Smith Asset Management Group LP purchased a new stake in shares of Idexx Laboratories Inc. (NASDAQ:IDXX) during the second quarter, according to its most recent disclosure with the SEC. The firm purchased 134,260 shares of the company’s stock, valued at approximately $12,467,000.

A number of other institutional investors have also added to or reduced their stakes in IDXX. Fundsmith LLP boosted its position in Idexx Laboratories by 69.0% in the first quarter. Fundsmith LLP now owns 4,210,679 shares of the company’s stock valued at $329,780,000 after buying an additional 1,719,511 shares during the last quarter. Norges Bank acquired a new position in Idexx Laboratories during the fourth quarter valued at about $59,478,000. Renaissance Technologies LLC boosted its position in Idexx Laboratories by 242.6% in the first quarter. Renaissance Technologies LLC now owns 437,504 shares of the company’s stock valued at $34,265,000 after buying an additional 309,804 shares during the last quarter. Old Mutual Global Investors UK Ltd. boosted its position in Idexx Laboratories by 270.4% in the second quarter. Old Mutual Global Investors UK Ltd. now owns 270,088 shares of the company’s stock valued at $25,080,000 after buying an additional 197,177 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in Idexx Laboratories by 43.2% in the first quarter. Goldman Sachs Group Inc. now owns 391,756 shares of the company’s stock valued at $30,683,000 after buying an additional 118,115 shares during the last quarter. Institutional investors own 91.58% of the company’s stock.

Shares of Idexx Laboratories Inc. (NASDAQ:IDXX) traded up 0.21% during midday trading on Wednesday, hitting $112.07. The stock had a trading volume of 508,590 shares. The company has a market cap of $10.03 billion, a P/E ratio of 50.80 and a beta of 0.56. Idexx Laboratories Inc. has a one year low of $63.48 and a one year high of $115.06. The firm has a 50 day moving average of $110.94 and a 200-day moving average of $92.35.

Idexx Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.62 by $0.12. Idexx Laboratories had a net margin of 11.94% and a negative return on equity of 414.67%. The business had revenue of $467 million for the quarter, compared to analysts’ expectations of $444.83 million. During the same quarter last year, the company posted $0.60 earnings per share. The company’s quarterly revenue was up 12.9% compared to the same quarter last year. On average, analysts forecast that Idexx Laboratories Inc. will post $2.36 earnings per share for the current fiscal year.

Several equities analysts have issued reports on IDXX shares. Zacks Investment Research upgraded Idexx Laboratories from a “hold” rating to a “buy” rating and set a $106.00 target price on the stock in a research report on Monday, July 25th. Stifel Nicolaus boosted their target price on Idexx Laboratories from $120.00 to $125.00 and gave the stock a “buy” rating in a research report on Tuesday, August 16th. Canaccord Genuity reiterated a “buy” rating on shares of Idexx Laboratories in a research report on Tuesday, August 2nd. Finally, Northcoast Research upgraded Idexx Laboratories from a “sell” rating to a “neutral” rating in a research report on Wednesday, August 3rd. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $105.20.

In other news, Chairman Jonathan W. Ayers sold 60,000 shares of the stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $107.69, for a total transaction of $6,461,400.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director William T. End sold 5,000 shares of the stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $108.50, for a total transaction of $542,500.00. Following the transaction, the director now directly owns 53,564 shares in the company, valued at approximately $5,811,694. The disclosure for this sale can be found here. Insiders own 2.79% of the company’s stock.

About Idexx Laboratories

5 Day Chart for NASDAQ:IDXX

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Idexx Laboratories Inc. (NASDAQ:IDXX).

Receive News & Ratings for Idexx Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.